The Johns Hopkins University spinout's MycoMeia Aspergillus Assay is used to aid the diagnosis of the lung disease aspergillosis in immunocompromised patients.

The firm said it is in talks with payors about pilot programs and it expects to soon publish data on the use of its test to improve outcomes and reduce healthcare costs.

The firm saw an increase in diagnostics solutions sales in the second quarter, particularly within its QuantiFeron and QiaStat-Dx businesses.

As part of the deal, the company is acquiring a "significant library of potential applications" of the test's exosome-based technology.

The firm anticipates lower-than-previously-expected COVID test sales will be offset by shifts in trade policy and tariff mitigation efforts.

The company also announced it would be divesting its Exosome Diagnostics business and selling it to MDxHealth.

Including its COVID-19-related business, the company's second quarter revenues were down 43 percent year over year.

At ADLM, the company provided a preview of its Liaison Nes point-of-care PCR instrument that is complementary to the firm's Liaison Plex syndromic testing system.

Developed as part of a broader collaboration between the two firms, the tool uses generative AI to let providers ask questions and describe conditions in plain language.

Cemhan Biricik, CEO of Fast Lab Technologies, and Martin Perlin, its medical director, are alleged to have billed public and private payors for testing that was never done.

The laboratory medicine organization is focused on the benefits of using data science within laboratories to more effectively care for patients and track utilization.

The firm expects to see growth in its life science business, in particular after it showed positive signs during the second quarter.